ArticleNature reviews. Clinical oncology2024

Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma.

Edward R Scheffer Cliff et al.PubMed ↗Publisher ↗

No numbers read from the abstract.